Hitachi invests in stem cell research to spur investor returns
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
Tokyo
WITH its network of tubes and petri dishes, Hitachi Ltd's latest gizmo may look more like a mini laboratory inside a refrigerator than the growth engine that the Japanese technology company envisages.
Its cabinet-sized stem cell incubator, unveiled in a research centre last month, promises to utilise a technique pioneered by Nobel Prize winner Shinya Yamanakato speed new eye and heart treatments - as well as catapult Tokyo-based Hitachi into the regenerative medicine business. It is one of the latest innovations for the company that has as many patents as General Electric Co and Siemens AG combined, and which plans to beef up research to spur investor returns that have lagged overseas rivals the past year.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
20 photos that show how dramatically Singapore has changed in two decades
Singapore’s key exports up 15.3% in March from electronics surge, exceeding forecasts
